Prevention of cervical, vaginal, and vulval cancers: Role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine

International Journal of Women's Health

Volumn 1, Issue 1, 2009, Pages 119-129

  Diaz, Maria Lina ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; Human papillomavirus; Quadrivalent vaccine; Vaginal cancer; Vulvar cancer

Indexed keywords

CAPSID PROTEIN L1; MESSENGER RNA; ORAL CONTRACEPTIVE AGENT; PLACEBO; VIRUS DNA; WART VIRUS VACCINE;

CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CHLAMYDIA TRACHOMATIS; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INJECTION SITE PAIN; KERATINOCYTE; LIFESTYLE MODIFICATION; NAUSEA; PANCREAS CANCER; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL BEHAVIOR; SOCIAL STATUS; SWELLING; SYNCOPE; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS REPLICATION; VULVA CANCER;

EID: 77953438183     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s4517     Document Type: Review

References (53)

1. Chang MH. Cancer prevention by vaccination against Hepatitis B. Recent results. Cancer Res. 2009;181:85-95.
2. De Villiers EM, Fauquet C, Broker, TR, Bernard HU, zur Hausen H. Classification of human papillomaviruses. Virology. 2004;324(1):17-27.
3. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny and taxonomy. J Virol. 1995;69(5):3074-3083.
4. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. Vol 64. Lyon (France): International Agency for Research on Cancer; 1995.
5. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic disease. Vaccine. 2006;24(Suppl 3):S26-S34.
6. Smith J, Backes D, Hoots R, Kurman R, Pimenta J. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol. 2009;113(4):917-924.
7. Insinga R, Liaw KL, Johnson L, Madeleine M. A systemic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1611-1622.
8. Hoots BE, Palefsky JM, Pimenta M, Smith JS. Human Papillomavirus type distribution in anal cancer and anal intraepethilial lesions. Int J Cancer. 2009;124(10):2375-2383.
9. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-1956.
10. Myers E. The ecomomic impact of HPV vaccines; not just cervical cancer. Am J Obstet Gynecol. 2008:198(5):487-488.
11. Centers for Disease Control. The national breast and cancer cervical cancer early detection program-reducing mortality through screening. http://www.cdc.gov/cancer/nbccedp/bccpdfs/BCC-FS2003 Update. pdf.2006. Accessed Aug 24, 2009.
12. American Cancer Society. Cancer facts and figures 2008. http://www.americancancersociety.org. Accessed Aug 24, 2009.
13. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005:55(2):74-108.
14. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Eng J Med. 1999;341(22):1633-1638.
15. Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R, et al. High prevalence of human papillomavairus (HPV) infection and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol. 2002;40(9):3341-3345.
16. Penn I. Cancers of the anogenital region in renal transplant patients. Cancer. 1986;58(3):611-616.
17. Herrington CS. Human papillomavirus and cervical neoplasia. II. Interaction of HPV with other factors. J Clin Path. 1995;48(1):1-6.
18. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, et al. Herpes simplex virus-2 as a human Papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002;94(21):1604-1613.
19. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: pooled analysis of the IARC multicentric case-control study. Cancer Causes Control. 2003;14(9):805-814.
20. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. International agency for research on cancer. Multicentric cervical cancer study group. Effect of oral contraceptives on risk of cervical cancer in women with human Papillomavirus infection; the IARC multicentric case-control study. Lancet. 2002;35(9312)9:1085-1092.
21. Einstein MH, Leanza S, Chiu LG, Schlecht NF, Goldberg GL, Steinberg BM, et al. Genetic variants in TAP are associated with high-grade cervical neoplasia. Clin Cancer Res. 2009;15(3):1019-1023.
22. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71-96.
23. Creaseman WY. Vaginal cancers. Curr Opin Obstet Gynecol. 2005;17(1):71-76.
24. Merino MJ. Vaginal cancer: the role of infectious and environmental factors. Am J Obstet Gynecol. 1991;1651:1255-1262.
25. Shah CA, Goff BA, Lowe K, Peters WA. Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol. 2009; 113(5):1038-1045.
26. U.S. Cancer Statistics Working Group. United States cancer statistics; 1999-2002 incidence and mortality Web based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2005. http://www.cdc.gov/cancer/npcr/uscs. Accessed Aug 24, 2009.
27. Info.cancerresearchuk.org/cancerstats/types/vulva.
28. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human Papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. Obstet Gynecol. 1997;89(1):81-84.
29. Berek JS, Hacker NF, eds. Practical Gynecologic Oncology. 3rd edition. Philadephia: Lippincott Williams & Wilkins; 2000.
30. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia:2004 modif ied terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005;50(11):807-810.
31. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol. 2005;106(6):1319-1326.
32. Villa LL, Ault KA, Giuliano AR, Cosota RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of vaccine targeting human Papillomavirus types 6, 11, 16, 18. Vaccine. 2006;24(27-28):557-583.
33. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Alvarez FF, Chiacchierini LM, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
34. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-6 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol 2006;107(1):18-27.
35. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human Papillomavirus (types 6, 11, 16, 18) L1 virus-like particles vaccine in young women: A randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-278.
36. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. Efficacy of prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through up to 5 years of follow-up. Br J Cancer. 2006;95(11):1459-1466.
37. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med 2007;356(19):1928-1943.
38. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915- 1927.
39. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus ( types 6, 11, 16, 18) L1 virus-like particle vaccines against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet. 2007;369(9574):1693-1702.
40. Villa L. Efficacy of a quadrivalent HPV (types 6,11,16, 18) L1 VLP vaccine against external genital disease: a combined analysis. 6th European Research Organizatioin on Genital Infection and Neoplasia (EUROGIN), Paris, France. April 23-26, 2006:4-24.
41. Rambout L, Hopkin L, Hotton B, Fergusson D. Prophylactic vaccination against human papillomavirus infections and disease in women: a systemic review of randomized control trials. CMAJ. 2007;177(5):469-479.
42. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naïve women aged 16-26 years. J Infect Dis 2009;199(7):926-935.
43. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adults. Pediatrics. 2006;118(5):2135-2145.
44. Information from CDC and FDA on the Safety of Gardasil Vaccine. http://www.fda.gov/cber/safety/gardasil071408.htm. Accessed Aug 24, 2009.
45. Press release. http://www.aan.com/press/index.cfm?fuseaction=release. view&release=692. Accessed Aug 24, 2009.
46. Brotherton HM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Llyod S, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008;179(6):525-533.
47. Olsson Se, Villa LL, Costa Rl, Petta Ca, Andrarde RP, Malm C, et al. Induction of immune memory follwing administration of prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931-4939.
48. Beller U, Abu-Rustum NR. Cervical cancers after human papilloma vaccination. Obstet Gynecol 2009;113(2 Pt 2):550-552.
49. Kulasingam SL, Myers ER. Potential health and economic impacts of adding a Human Papillomavirus vaccine to screening programs. JAMA. 2003;290(6):781-789.
50. Krustrup D, Jensen HL,van den Brule AJ, Frisch M. Histological characteristics of human Papillomavirus-positive and negative invasive and in situ squamous cell tumours of the penis. Int J Exp Pathol 2009;90(2):182-189.
51. Lehtinen M, Apter D, Dubin G, Kosunen E, Isakssan R, Korpivaara E, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS. 2006;17(8):517-521.
52. Wong LP. Preventing cervical cancer through human papillomavirus vaccination: perspective from focus groups. J Low Genital Tract Dis 2009;13(2):85-93.
53. Diaz ML. Human papillomavirus - prevention and treatment. Obstet Gynecol Clin North Am. 2008;35(2):199-217, vii-viii.